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ABSTRACT
Introduction: Hemotherapy consists of therapeutic treatments performed through 
blood transfusion. Clinical and serological screening of donors is an essential strategy 
to avoid transmission of infectious agents in blood transfusion. The objective of this 
study is to assess the seroprevalence of HIV infection, syphilis and syphilis/HIV 
coinfection in blood donors from a blood bank in Porto Alegre from 2014 to 2016.
Methods: Retrospective analysis of all blood donors registered on a software for 
managing hemotherapy services (Hemodot) of the Blood Bank in the Marques Pereira 
Laboratory, Porto Alegre / RS, from 2014 to 2016.
Results: Of the 28,173 users of the hemotherapy service during the study 
period, 198 (0.70%) were positive for syphilis, HIV infection, or syphilis/HIV co 
infection. The prevalence of positive results for syphilis was 0.3%, 0.57% and 
0.70% in 2014, 2015 and 2016, respectively, and for HIV infection was 0.18%, 0.14%, 
and 0.16% for the same period. However, the prevalence of syphilis/HIV coinfection 
was not statistically significant.
Conclusions: The prevalence of syphilis increased significantly from 2014 to 2016. 
Hovever, this did not occur with HIV infection or with coinfection. This finding may reflect 
the requirement of the nucleic acid technique (NAT) for HIV screening in blood banks, 
a procedure that has been increasing transfusion safety and reducing the window 
period. Further studies may shed new light on the combined use of serological tests 
and NAT assays in blood banks to diagnose HIV cases and syphilis/HIV coinfection.
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Blood donation is a topic of global importance, especially with regard to 
blood transfusion safety1. Hemotherapy is a therapeutic treatment consisting 
of blood transfusion or transfusion of blood products and poses a high 
epidemiological risk, since blood, as a living tissue, is able to transmit several 
diseases2. Thus, quality parameters must be rigorously followed for blood 
procurement and for the selection and protection of recipients and donors3.
In Brazil, hemotherapy procedures are currently governed by a technical 
regulation of the Brazilian National Health Surveillance (Agência Nacional de 
Vigilância Sanitária, ANVISA): Ordinance no. 158, dated February 4, 2016, 
published in the Federal Official Gazette of February 5, 2016 (no. 2, Section 1, 
page 37)4. This ordinance aimed to establish procedures to prevent the 
transmission of infection and improve the quality of the blood component to 
be transfused. The process of blood donation is conducted under a rigorous 
system divided into stages beginning with donor procurement and finishing 
with transfusion of donor’s blood to the recipient The first stage, known as 
clinical screening, consists of taking the medical history of donor candidates 
to analyze their clinical history and their health behavior. The second stage 
is serological screening, which is the most common form of preventing the 
transmission of several etiologic agents5,6. In this context, after donation, 
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blood undergoes laboratory screening, including 
immunohematologic tests, serological tests, and acid 
nucleic test (NAT)7,8. These regulations ensure blood 
donation safety. The article no. 130 of Ordinance 
no. 158/16 sets out mandatory highly sensitive 
laboratory serological tests to detect markers for 
the following conditions: syphilis, Chagas disease, 
hepatitis B, hepatitis C, human immunodeficiency 
virus (HIV), and human T-cell lymphotropic virus type 
I and/or II (HTLV I/II)4. Additionally, NAT started to be 
implemented according to the Brazilian legislation7. 
In some blood banks in the city of São Paulo, it was 
implemented to reduce HIV and hepatitis C virus 
(HCV) transmission by blood transfusion and became 
mandatory for the entire Brazilian blood transfusion 
network, including public and private blood banks, 
in February 2014 under Ordinance no. 2712 dated 
November 12, 20138.
It is known that the disease most commonly 
transmitted by blood transfusion are hepatitis C 
and HIV. However, an important association has 
been observed between syphilis and HIV in recent 
years, especially with regard to their window periods. 
Therefore, screening tests in blood bank should be 
able to identify donors presenting with these diseases9.
Syphilis is a chronic infectious disease caused 
by the spirocheteTreponema pallidum10. For an 
effective diagnosis of syphilis, serological screening 
with non-treponemal and/or treponemal tests are 
recommended. Non-treponemal tests include 
venereal disease research laboratory (VDRL)) and 
rapid plasma reagin. Diagnosis is confirmed using 
treponemal tests, such as fluorescent treponemal 
antibody-Abs (FTA-Abs), Treponema Pallidum 
hemagglutination test, TPHA, and enzyme-linked 
immunosorbent assay, ELISA )11,12. Treatment for 
this condition is well-established, with penicillin as 
the drug of choice. Recently, bacterial resistance to 
this drug has made syphilis a public health problem 
and the production of penicillin has become scarce. 
Intramuscular benzathine penicillin is the drug of 
choice in most cases, except for congenital syphilis 
and neurosyphilis, when crystalline penicillin G sodium 
is indicated13,14. However, even when treatment is 
effective, results for treponemal tests remain positive, a 
phenomenon known as serological scar15,16. From 2010 
to June 2016, the Notifiable Diseases Information 
System (Sistema de Informação de Agravos de 
Notificação, SINAN) notified a total of 227,663 cases 
of syphilis acquired in Brazil, 62.1% coming from 
the southeastern region of the country, 20.5% from 
the southern region, 9.3% from the northeastern 
region, 4.7% from the midwestern region, and 3.4% 
from the northern region. Overall, 136,835 cases were 
male and 90,755 were female. Moreover, patients 
aged from 20 to 29 years accounted for 31.2% of 
the cases. In 2015, 65,878 cases of syphilis were 
notified, of which 39,638 (60.2%) were male and 
26,220 (39.8%) were female17.
HIV, the causative agent of acquired immunodeficiency 
syndrome (AIDS), is a retrovirus classified into the 
subfamily Lentiviridae and containing RNA genetic 
material18. Brazil is one of the countries that provides 
free universal antiretroviral (ARV) therapy19. The use of 
this drug to treat HIV infection has reduced morbidity 
and mortality rates, thus increasingly making AIDS 
a chronic controllable disease worldwide20.
HIV infection is diagnosed using serological tests 
through ELISA, enzyme linked fluorescent assays, 
immunofluorescence assays, particle agglutination 
assays chemiluminescence assays, and microparticle 
enzyme immunoassays9. Blood banks are required 
by the Brazilian Ministry of Health to perform tests 
that detect antibodies against HIV, regardless of the 
method or allow for the combined detection of antibody 
against HIV + HIV p24 antigens and tests that aim to 
detect HIV nucleic acid. To ensure transfusion, one 
positive test is already considered and indication for 
discarding blood bags4. The implementation of the 
NAT in the testing routine for the laboratory detection 
of the virus reduced the estimated window period 
compared with serological tests for HIV detection 
from 22 to 10 days21.
From 2007 to June 2016, SINAN notified 136,945 cases 
of HIV infection in Brazil, 71,396 (52.1%) coming from 
the southeastern region, 28,879 (21.1%) from the 
southern region, 18,840 (13.8%) from northeastern 
region, 9,152 (6.7%) from the midwestern region, 
and 6,868 (6.3%) from the northern region. 
Overall, 92,149 of patients were male and 44,766 were 
female, and 52.3% were aged fro 20 to 34 years old. 
In 2015, 32,321 cases of HIV infection were notified, 
22,672 (70.2%) in male and 9,637 (29.8%) in female22.
Both syphilis and HIV are transmitted mainly by 
unprotected sex. However, the presence of syphilis 
increases the risk of contracting HIV from ulcerated 
genital lesions, mucosal disruption, inflammation, 
and genital secretions. Therefore, all patients with 
syphilis should undergo HIV testing, and all positive 
HIV patients should be tested for syphilis on a regular 
basis23-25.
Several studies reported that syphilis, such 
as other acute infections, leads to increased viral 
load and reduced CD4 cell count. This transient 
increase in viral load results in increased risk for 
HIV transmission among patients with the two 
diseases and is a consequence of activation of 
immunological response26-28. Studies suggest that 
the window period for syphilis may predispose to 
HIV infection, i.e., HIV transmission is facilitated in 
patients with syphilis because both conditions share 
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the same route of transmission. Additionally, the base 
of primary chancre of syphilis have a high number 
of T cells and macrophages, which are the primary 
targets of HIV9,25,29.
The window period of syphilis is short, since tests 
may yield positive results some days after the onset 
of primary stage lesions30. Some tests, such as VDRL, 
RPR, TPHA, and FTA-abs, become positive within 
from 3 weeks to 3 months; Conversely, tests for 
antibody against HIV become positive within 6 weeks 
from 3 months, whereas Western blot and p24 antigen 
tests, within 2 weeks31. Within this context, the 
present study sought to evaluate the prevalence of 
HIV infection, syphilis, and syphilis/HIV coinfection 
in blood donors from a blood bank in Porto Alegre, 
southern Brazil, from 2014 to 2016.
METHODS
A quantitative, descriptive, retrospective study 
was carried out to analyze information from all blood 
donors registered at the database of the blood bank 
of Laboratório Marques Pereira at Porto Alegre, 
southern Brazil, for the period from January 1st, 2014 to 
December 31, 2016. This study was approved by the 
Research Ethics Committee of Centro Universitário 
Metodista IPA and registered at Platarforma Brasil 
(protocol number 1.709.050).
The sample of the present study included data from 
28,173 hemotherapy service users at the Laboratório 
Marques Pereira. Data records were assessed using 
a software for managing hemotherapy services 
(Hemodot) to collect information on HIV I/II serology, 
NAT assays, VDRL serology for syphilis to analyze 
the frequency of these contagious diseases whether 
alone or in combination among the study population. 
To that end, data were inserted into the Statistical 
Package for Social Sciences (SPSS) software and 
analyzed considering a level of significance of p<0,05.
Results were expressed as numbers and 
percentages. In the blood bank under studies, donor 
blood were assessed by chemiluminescent microparticle 
immunoassays with specificity of 99.5% and sensitivity 
of 100%, as recommended by the Brazilian Ministry 
of Health. According to manufacturer’s instructions, 
samples with serological values ≥ 1 are reactive 
and < 1 are not. However, our service establishes a 
margin of safety of 15% (grey zone), recommending 
that results within this zone should be considered 
indeterminate and donors should be asked to return 
to the service to have blood drawn again.
RESULTS
The total number of donor candidates from 2014 to 2016 
was 28,173 donors, distributed as follows: 8,695 in 
2014, 10,009 in 2015, and 9,469 in 2016. Over the 
3-year period, the number of blood bags positive for 
syphilis, HIV infection, and syphilis/HIV coinfection 
was 198 (0.70%). Data for positive serological and 
NAT assays are presented in Table 1.
The prevalence of syphilis-positive blood bags 
gradually increased over the years, while the 
prevalence of HIV-positive cases did not change 
significantly. All reactive serological HIV tests were 
confirmed by NAT assays, which were also positive 
for HIV infection. The prevalence of syphilis in blood 
donor is greater compared with that of HIV cases. 
Conversely, the prevalence of syphilis/HIV coinfection 
was not statistically significant, as shown in Figure 1.
Table 1: Total of positive cases of syphilis, HIV, and syphilis/HIV coinfection per year.
Total (%) Men (%) Women (%)
2014
Positive results for syphilis 26 (0.3) 15 (0.17) 11 (0.13)
Positive results for HIV infection 16 (0.18) 13 (0.15) 3 (0.03)
Positive results for syphilis/HIV coinfection 0 (0.0) 0 (0.0) 0 (0.0)
Total of donors/year 8695 (100)
2015
Positive results for syphilis 57 (0.57) 33 (0.33) 24 (0.24)
Positive results for HIV infection 14 (0.14) 9 (0.09) 5 (0.05)
Positive results for syphilis/HIV coinfection 3 (0.03) 3 (0.03) 0 (0.0)
Total of donors/year 10009 (100)
2016
Positive results for syphilis 66 (0.70) 34 (0.36) 32 (0.34)
Positive results for HIV infection 15 (0.16) 4 (0.04) 11 (0.12)
Positive results for syphilis/HIV coinfection 1 (0.01) 1 (0.01) 0 (0.0)
Total of donors/year 9469 (100)
Source: designed by the author.
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DISCUSSION
Currently, there is a clear concern from hemotherapy 
services in ensuring blood transfusion safety both for 
donors and recipients, which has been increasing 
reducing the frequency of transmission of infectious 
diseases by blood transfusion. This reduction may 
be achieved through effective screening for these 
diseases in blood banks, including donor procurement, 
epidemiological and clinical analysis of donor health 
status, and laboratory screening, in order to prevent 
the risk of contamination and thus increase safety
Our findings revealed the prevalence of positive 
serology for syphilis increased on an yearly basis from 
2014 to 2016. This fact may be explained by the high 
prevalence of syphilis in the general population, by 
the shortage of penicillin (the antibiotic of first choice 
for the treatment of syphilis), and by the fact that most 
infections are diagnosed after solidarity initiatives such 
as blood donation, and promotes the spread of both 
infections. This finding corroborates surveillance data 
showing that the prevalence of syphilis increased 
42.7% in 201517. Conversely, positive HIV serology 
remained stable over the 3-year period. These findings 
may be justified by the mandatory implementation of 
NAT assays for HIV infection in blood banks, which 
reduced the window period, because of the sensitivity 
of the test, since it is required to have a sensitivity of 
100%, with no acceptable false negatives4.
In a study conducted between December 2011 
and May 2012 at the blood bank of the Edéa Regional 
Hospital, Cameroon, the seroprevalence of HIV 
was 4.1%, indicating a reduction in HIV cases in the 
country over the last decade due to the implementation 
of prevention programs32,33.
In the present study, the prevalence of HIV infection, 
syphilis, and HIV/syphilis coinfection from 2014 to 2016 
was higher in males. A study conducted by Rohr et al. 
to assess the profile of unfit donor candidates at the 
hospital of Santo Ângelo, southern Brazil found that 
the main cause for ineligibility in men was high risk 
behavior and multiple sex partners. This may result 
from greater sexual freedom, homosexual behavior, 
extramarital affairs, and reduced use of condoms, all 
of which make men more susceptible to contract a 
sexually transmitted disease. Conversely, the main 
cause for ineligibility in women was low hemoglobin 
or hematocrit. This behavioral information obtained 
from the study by Rohr et al. may explain the results 
from the present study showing a higher prevalence 
of syphilis in men.
With a prevalence of 0.014%, HIV/syphilis coinfection 
was not very prevalent in the study population from 
2014 to 2016, although the two diseases share the 
same route of transmission. In contrast, a previous 
study conducted at Hemocentro de Guarapuava, 
southern Brazil found a much higher prevalence 
of HIV/syphilis coinfection. From January 2009 to 
December 2013, there were 28,851 blood donations, 
of which 1,651 (5.6%) were positive for infectious 
diseases. Of the 1,651 positive donations, 76 (4.7%) 
were coinfected with syphilis/HIV34. In the present study, 
which covered from 2014 to 2016, the non-statitiscally 
significant prevalence of syphilis/HIV coinfection 
(0.014%) may be explained by the period of data 
collection and by the peculiarites of the blood bank 
under study, which also represents a limitation of 
this study. It is important to note that a positive HIV 
serology does not mandatorily mean positive syphilis 
serology. One condition is known to predispose to 
the other, but there is no dependence relationship 
between them. The analysis of coinfection with 
these diseases has an important role in assessing 
the window period and may provide data for future 
epidemiological studies to help treatment of positive 
cases, since both conditions share the same route 
of infection.
A study conducted in Campinas, southeastern 
Brazil, assessed the prevalence of syphilis/HIV 
coinfection in patients registered on an electronic 
system for the notification of sexually transmitted 
diseases (STD) (SINDST) at a STD/HIV referral 
center from January 2004 to December 2012. 
Overall, 3,106 cases of STD were notified. Of these, 
860 presented with at least one episode of syphilis. 
Of the patients with syphilis, 781 (90.8%) were male 
and 79 (9.2%) were female. In turn, there were 
377 (43.8%) cases of syphilis/HIV coinfecction, of 
which 354 were male and 23 were female35. Another 
study conducted from 1997 to December 2014 in Rio 
de Janeiro, southern Brazil, with HIV seropositive 
patients assessed the prevalence of syphilis/HIV 
during HIV treatment. Of 793 HIV-positive patients, 
417 met study requirements, of which 270 (64.7%) 
Figure 1: Prevalence of positive serology for syphilis, HIV 
infection, and syphilis/HIV infection in the blood bank of 
Laboratório Marques Pereira from 2014 to 2016; *results 
with a significance level of p < 0.05. Source: designed by 
the author.
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were male, 141 (33.8%) were female, and 6 (1.4%) 
were transvestite/transexual. When only coinfected 
patients were analyzed, 81 met study requirements, 
of which 67 (82.7%) were male, 10 (12.3%) were 
female, and 4 (4.4%) were transvestite/transexual36. 
The prevalence of syphilis/HIV coinfection was 19.4%; 
however, it is worth noting that the period covered 
in the study was long and that there may have been 
a change in the epidemiological profile of the study 
over this period.
A cross-sectional study determined the prevalence 
of syphilis and factors associated with syphilis infection 
in patients with HIV/AIDS treated at Hospital Santa 
Casa de Misericórdia de Vitória, southeastern Brazil, 
from August 2010 to September 2011. Of 498 patients 
selected, 438 (88%) HIV-positive patients HIV were 
included in the study, of which 241 (55%) were male 
and 197 (45%) were female. Of the 438 HIV-positive 
patients, 23 (5.3%) were coinfected with syphilis, 20 
(87%) men and 3 (13%) women37. Another study 
conducted in Porto Alegre, southern Brazil, assessed 
the prevalence of coinfection with syphilis in HIV 
seropositive patients from 1991 to November 2008. 
Of 2,262 patients infected with HIV, only 1,012 met 
criteria for inclusion in the study. Of these, 580 (57%) 
were male and 432 (43%) were female. The prevalence 
of syphilis/HIV coinfection in this study was 20,5% 
(208 cases, 166 men and 42 women)38. It is worth 
emphasizing that there was a great variation in the 
results found in the literature, resulting from differences 
in study design, diagnostic tests, and study period.
Technological and scientific advances are 
remarkably improving attempts to minimize the risks 
posed by blood transfusion. Fourth-generation ELISA 
assays have a sensitivity of nearly 100%. Recently, 
the mandatory implementation of nucleic acid 
amplification test for the screening of HIV and HCV in 
blood banks has reduced the window period. It should 
be noted that this study aimed to assess coinfection 
in blood donors from a blood bank in Porto Alegre, 
southern Brazil. However, there is scarce clinical 
evidence on the topic in the literature. Thus, further 
studies covering different study periods are needed 
to investigate satisfactory results and to explain the 
findings obtained in the present study. Therefore, 
this study sheds new light on the combined use of 
serological tests and NAT assays in blood banks to 
diagnose HIV cases and syphilis/HIV coinfection.
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